Bugalho A. et al. evaluated the use of EBUS-TBNA combined with flow cytometry and reverse-transcription quantitative polymerase chain reaction (RT-qPCR) to identify tumor-associated antigens: EpCAM, cytokeratin-19 (CK-19), carcinoembryonic antigen (CEA), and CD44 in patients with NSCLC. Here, CD44 is linked to neoplasm.